Table 3.
Lymphoma responses following anti-HCV treatment in HCV-associated indolent NHLs.
| Reference | No. of patients | Lymphoma subtype | MC | Antiviral treatment |
Hematological response |
||||
|---|---|---|---|---|---|---|---|---|---|
| IFN | IFNαRBV | PegIFN/RBV | IFN/DAAs | ORR | CR | ||||
| Hermine et al. [2002] | 9 | SLVL (9) | 6 | 7 | 2 | 0 | 9 (100%) | 8 (89%) | |
| Kelaidi et al. [2004] | 8 | SLVL (3) | 8 | 2 | 1 | 5 | 5 (62%) | 5 (62%) | |
| SMZL (1) | |||||||||
| EMZL (2) | |||||||||
| Disseminated MZL (2) | |||||||||
| Saadoun et al. [2005] | 18 | SLVL (18) | 18 | 8 | 10 | 0 | 18 (100%) | 14 (78%) | |
| Vallisa et al. [2005] | 13 | LPL (4) | 5 | 0 | 0 | 13 | 9 (69%) | 7 (54%) | |
| SMZL (4) | |||||||||
| NMZL (2) | |||||||||
| EMZL (2) | |||||||||
| FL (1) | |||||||||
| Mazzaro et al. [2009] | 18 | LPL (16) | 13 | 0 | 8 | 10 | 13 (72%) | 9 (50%) | |
| SLVL (1) | |||||||||
| FL (1) | |||||||||
| Pellicelli et al. [2011] | 9* | SMZL (3) | 5 | 0 | 0 | 9 | 7 (78%) | 5 (55%) | |
| EMZL (3) | |||||||||
| FL (2) | |||||||||
| NMZL (1) | |||||||||
| Arcaini et al. [2014] | 100$ | SMZL (23) | 35 | 10‡ | 23 | 63 | 77 (77%) | 54 (54%) | |
| NMZL (12) | |||||||||
| EMZL (25) | |||||||||
| LPL (7) | |||||||||
| FL (5) | |||||||||
| CLL/SLL (1) | |||||||||
| Others (27) | |||||||||
| Michot et al. [2015] | 14 | MZL (14) | n.a. | 0 | 8 | 6 | 11 (78%) | 8 (57%) | |
Only nine patients receiving antiviral treatment as first-line therapy are reported.
Only 100 patients treated with antiviral treatment frontline are reported.
Four additional patients received PegIFNα alone.
CLL/SLL, chronic lymphocytic leukemia/small cell lymphocytic lymphoma; CR, complete response; DAA, new direct antiviral agent; EMZL, extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue; FL, follicular lymphoma; HCV, hepatitis C virus; IFN, interferon α; LPL, lymphoplasmacytic lymphoma; MC, mixed cryglobulinemia; MZL, marginal zone lymphoma; n.a., not applicable; NHL, non-Hodgkin’s lymphoma; NMZL, nodal marginal zone lymphoma; PegIFN, pegylated interferon α; ORR, overall response rate (complete + partial responses); RBV, ribavirin; SLVL, splenic marginal zone lymphoma with villous lymphocytes; SMZL, splenic marginal zone lymphoma.